CLChristina Lamers

Christina Lamers

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christina Lamers has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Phage Display-Derived Cyclic Peptides as Ligand-Specific Modulators for β 2 -Integrin Receptors

    by Carla Johanna Sommer-Plüss, Stephanie Anita Vogt, Lorella Ciullo, Riccardo Mancuso, Tom Götze-Ebert, Lilli Kehr, Daniel Ricklin, Christina Lamers

    The leukocyte-specific β 2 -integrin receptor family exerts a wide range of functions: β 2 -integrins are involved in leukocyte trafficking, where they mediate cell adhesion during inflammatory responses via binding to ICAM-1, ICAM-2, or JAM-C. Furthermore, they are essential for the recognition and phagocytosis of pathogens opsonized by complement. Accordingly, the β 2 -integrin family is known to be involved in autoimmune and inflammatory diseases, such as systemic lupus erythematosus. Owing to their complex biology, involving multiple conformational transitions, different signaling pathways, and a broad spectrum of ligands, the development of β 2 -integrin-targeted probes and therapeutics has remained challenging. We aimed to develop macrocyclic peptides, derived from phage display screening, which can be used to unravel ligand binding profiles of β 2 -integrins with an emphasis on the αI domain. The selection of suitable lead peptides, and the characterization of their interaction profiles with different αI domains, was enabled by an established in-vitro assay platform. Various peptide sequences were enriched during several rounds of phage display against the αI-domain of CR3, of which two peptides with particularly low micromolar binding affinity were further characterized. Both peptides showed direct binding to β 2 -integrin αI-domains and, in a competitive assay, dose-dependent inhibition of the αI-domains’ interactions with their main ligands iC3b and ICAM-1, respectively. These ligand-interfering properties were confirmed in bead- and cell-based adhesion assays. The modulators developed here are expected to provide valuable insight into the (patho-)physiology of CR3 and the other members of the β 2 -integrin family, as the two peptides were able to compete with different ligands. In the future, this may help to identify potential therapeutic approaches for autoimmune, inflammatory, and age-related diseases.

  • Open Access

    New analogs of the compstatin family of clinical complement inhibitors with low picomolar target affinity

    by Stephanie Vogt, Alexander J. Lander, Ekaterina Umnyakova, Roman Aschwanden, Sarah E. Hughes, Oliver Schwardt, Markus A. Lill, Martin Smieško, John D. Lambris, Christina Lamers, et al.

    Macrocyclic peptides of the compstatin family have emerged as therapeutic complement system modulators. Alongside an approved PEGylated derivative, sequence-optimized compstatin analogs with enhanced PK/PD properties have shown clinical promise. By extending the structure-activity relationship of compstatin, we characterized a highly beneficial V3I modification that enhances compstatin’s target affinity up to 30-fold and show that the additional gamma-methyl group addresses a specific target pocket. Novel analog Cp01-V3I represents the most potent analog comprised entirely of canonical amino acids (KD = 20 nM), opening a path toward recombinant applications. Meanwhile, the V3I modification can be transferred to late-generation analogs to obtain a low-picomolar-affinity derivative (KD = 0.08 nM), termed Cp60, with potent complement inhibition in vitro. Lastly, we demonstrate that Cp60’s ultra-long target residence enables new applications as a diagnostic tool for the detection of complement opsonins on biosurfaces. Collectively, this work highlights the importance of vigorous optimization of de novo peptide inhibitors to improve PK/PD properties and enable novel applications.